Which has preferable valuation & earnings, ABVX or VERA?

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A

Is ABVX or VERA more profitable?

Vera Therapeutics' return on equity of -84.13% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Vera Therapeutics N/A -84.13% -66.79%

Does the media favor ABVX or VERA?

In the previous week, Vera Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat Vera Therapeutics' score of 0.81 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Vera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PRAX or VERA?

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Praxis Precision Medicines N/A N/A -$303.27M -$12.93 N/A Vera Therapeutics N/A N/A -$299.61M -$5.86 N/A

Is PRAX or VERA more profitable?

Praxis Precision Medicines' return on equity of -34.15% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -34.15% -32.42% Vera Therapeutics N/A -84.13% -66.79%

Does the media refer more to PRAX or VERA?

In the previous week, Vera Therapeutics had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 8 mentions for Vera Therapeutics and 6 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.41 beat Vera Therapeutics' score of 0.81 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VERA or KYMR?

In the previous week, Vera Therapeutics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.95 beat Vera Therapeutics' score of 0.81 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VERA or IONS?

In the previous week, Ionis Pharmaceuticals had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 8 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.81 beat Ionis Pharmaceuticals' score of 0.34 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 4 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PTGX or VERA?

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 8 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.81 beat Protagonist Therapeutics' score of 0.61 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vera Therapeutics (VERA) Competitors

$35.05 +1.45 (+4.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$34.80 -0.25 (-0.70%)

As of 09/11/2026 07:47 PM Eastern

Compare

VERA vs. ABVX, PRAX, KYMR, IONS, and PTGX

Should you buy Vera Therapeutics stock or one of its competitors? Vera Therapeutics's main competitors and comparable companies include Abivax (ABVX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Ionis Pharmaceuticals (IONS), and Protagonist Therapeutics (PTGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vera Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Abivax currently has a consensus target price of $156.38, indicating a potential upside of 31.81%. Vera Therapeutics has a consensus target price of $80.15, indicating a potential upside of 128.68%. Given Vera Therapeutics' higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

In the previous week, Vera Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Abivax. Abivax's average media sentiment score of 1.55 beat Vera Therapeutics' score of 0.81 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Vera Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Abivax shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abivax has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Vera Therapeutics' return on equity of -84.13% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Vera Therapeutics	N/A	-84.13%	-66.79%

Summary

Vera Therapeutics beats Abivax on 8 of the 12 factors compared between the two stocks.

How does Vera Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Praxis Precision Medicines' return on equity of -34.15% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Vera Therapeutics	N/A	-84.13%	-66.79%

Praxis Precision Medicines presently has a consensus target price of $585.95, suggesting a potential upside of 75.13%. Vera Therapeutics has a consensus target price of $80.15, suggesting a potential upside of 128.68%. Given Vera Therapeutics' higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Praxis Precision Medicines has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

In the previous week, Vera Therapeutics had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 8 mentions for Vera Therapeutics and 6 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.41 beat Vera Therapeutics' score of 0.81 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Praxis Precision Medicines and Vera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Kymera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Vera Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Kymera Therapeutics	$105M	91.04	-$311.35M	-$3.24	N/A

In the previous week, Vera Therapeutics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.95 beat Vera Therapeutics' score of 0.81 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Vera Therapeutics presently has a consensus price target of $80.15, suggesting a potential upside of 128.68%. Kymera Therapeutics has a consensus price target of $130.83, suggesting a potential upside of 13.81%. Given Vera Therapeutics' higher possible upside, equities analysts plainly believe Vera Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.88

99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vera Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Summary

Kymera Therapeutics beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Ionis Pharmaceuticals?

Vera Therapeutics (NASDAQ:VERA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Vera Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Ionis Pharmaceuticals	$944M	9.54	-$381.39M	-$3.46	N/A

In the previous week, Ionis Pharmaceuticals had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 27 mentions for Ionis Pharmaceuticals and 8 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.81 beat Ionis Pharmaceuticals' score of 0.34 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	4 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Vera Therapeutics currently has a consensus price target of $80.15, indicating a potential upside of 128.68%. Ionis Pharmaceuticals has a consensus price target of $91.25, indicating a potential upside of 68.33%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Vera Therapeutics is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vera Therapeutics has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Vera Therapeutics' return on equity of -84.13% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Summary

Vera Therapeutics beats Ionis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Protagonist Therapeutics has a net margin of 29.40% compared to Vera Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Vera Therapeutics	N/A	-84.13%	-66.79%

Protagonist Therapeutics presently has a consensus price target of $147.13, suggesting a potential downside of 0.71%. Vera Therapeutics has a consensus price target of $80.15, suggesting a potential upside of 128.68%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Protagonist Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

In the previous week, Protagonist Therapeutics had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 8 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.81 beat Protagonist Therapeutics' score of 0.61 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Summary

Protagonist Therapeutics beats Vera Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.42B	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-5.98	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	4.13	15.12	10.33	6.20
Net Income	-$299.61M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-2.34%	-4.34%	-3.32%	-2.35%
1 Month Performance	16.87%	-0.02%	-0.41%	-2.77%
1 Year Performance	47.45%	40.64%	19.21%	7.63%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	2.7883 of 5 stars	$35.05 +4.3%	$80.15 +128.7%	+42.9%	$2.42B	N/A	N/A	361	Analyst Forecast
ABVX Abivax	2.6108 of 5 stars	$114.79 flat	$156.50 +36.3%	+38.0%	$10.02B	N/A	N/A	61	News Coverage Positive News Analyst Upgrade
PRAX Praxis Precision Medicines	3.0013 of 5 stars	$351.81 flat	$585.95 +66.6%	+748.8%	$9.82B	$8.55M	N/A	110	News Coverage Positive News
KYMR Kymera Therapeutics	1.8089 of 5 stars	$117.39 flat	$128.70 +9.6%	+148.8%	$9.76B	$39.21M	N/A	170	Analyst Upgrade
IONS Ionis Pharmaceuticals	3.1981 of 5 stars	$58.09 flat	$94.20 +62.2%	-15.3%	$9.65B	$944M	N/A	1,402	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Vera Therapeutics compare to Abivax?

Summary

How does Vera Therapeutics compare to Praxis Precision Medicines?

Summary

How does Vera Therapeutics compare to Kymera Therapeutics?

Summary

How does Vera Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Vera Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. ABVX, PRAX, KYMR, IONS, and PTGX

How does Vera Therapeutics compare to Abivax?

Do analysts recommend ABVX or VERA?

Which has preferable valuation & earnings, ABVX or VERA?

Does the media favor ABVX or VERA?

Do insiders & institutionals have more ownership in ABVX or VERA?

Which has more risk and volatility, ABVX or VERA?

Is ABVX or VERA more profitable?

Summary

How does Vera Therapeutics compare to Praxis Precision Medicines?

Do insiders and institutionals hold more shares of PRAX or VERA?

Is PRAX or VERA more profitable?

Do analysts recommend PRAX or VERA?

Which has more risk & volatility, PRAX or VERA?

Which has better earnings & valuation, PRAX or VERA?

Does the media refer more to PRAX or VERA?

Summary

How does Vera Therapeutics compare to Kymera Therapeutics?

Which has preferable earnings & valuation, VERA or KYMR?

Does the media prefer VERA or KYMR?

Which has more volatility and risk, VERA or KYMR?

Do analysts prefer VERA or KYMR?

Do insiders & institutionals believe in VERA or KYMR?

Is VERA or KYMR more profitable?

Summary

How does Vera Therapeutics compare to Ionis Pharmaceuticals?

Which has stronger earnings and valuation, VERA or IONS?

Does the media prefer VERA or IONS?

Which has more risk & volatility, VERA or IONS?

Do analysts rate VERA or IONS?

Do insiders & institutionals have more ownership in VERA or IONS?

Is VERA or IONS more profitable?

Summary

How does Vera Therapeutics compare to Protagonist Therapeutics?

Is PTGX or VERA more profitable?

Do analysts recommend PTGX or VERA?

Do institutionals & insiders hold more shares of PTGX or VERA?

Which has preferable valuation and earnings, PTGX or VERA?

Does the media favor PTGX or VERA?

Which has more risk & volatility, PTGX or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools